High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest...
High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention
About this item
Full title
Author / Creator
Publisher
London: BMJ Publishing Group Ltd and British Cardiovascular Society
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group Ltd and British Cardiovascular Society
Subjects
More information
Scope and Contents
Contents
AimHigh on-clopidogrel platelet reactivity (HCPR) and high on-aspirin platelet reactivity (HAPR) are associated with atherothrombotic events following coronary stenting. There are, however, few data concerning high on-treatment platelet reactivity to both aspirin and clopidogrel simultaneously. The aim of the present study was to determine the inci...
Alternative Titles
Full title
High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_867723700
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_867723700
Other Identifiers
ISSN
1355-6037
E-ISSN
1468-201X
DOI
10.1136/hrt.2010.220491
